Primary Objective:
- To demonstrate that re-challenge with an oxaliplatin based regimen (modified FOLFOX-6)
will provide a clinical disease control rate (DCR) of at least 20% at the end of the
chemotherapy.
Secondary Objective:
- To evaluate other measures of tumour's responses and safety.